In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Aeterna Zentaris (NASDAQ: AEZS). The company’s shares opened today at $2.14.
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 9.5% and a 44.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Aeterna Zentaris has an analyst consensus of Moderate Buy, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.29 and a one-year low of $0.89. Currently, Aeterna Zentaris has an average volume of 192.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. It operates through biopharmaceutical segment. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Charleston, SC.
